Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $253.09M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.08M
Average 0.12M
PROF Other Financing Activities
Financing cash flows not reported separately.
Profound Medical Corp.NASDAQ: PROF
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities outflow grows to $75K
Q1 FY2026 other financing activities was $75K, compared with $0 a year earlier. Trailing-twelve-month other financing activities was -$941K.
Context
- Other financing activities amounted to 0.0% of revenue in FY2025, down 47.7 pp from a year earlier.
- Other financing activities increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other financing activities holds near $75K or moves back toward the trailing-twelve-month quarterly average of -$235.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- +100.0%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | +100.0% |
| FY2024 | 2024-12-31 | (4.85M) | -281.8% |
| FY2023 | 2023-12-31 | 2.67M | +2240.4% |
| FY2022 | 2022-12-31 | 114K | -98.2% |
| FY2021 | 2021-12-31 | 6.33M | — |
Other Financing Activities vs competitors
How PROF compares with its peers on the latest reported figures
- PROF's LTM Mar 2026 other financing activities of $941K is the 7th largest of the 11 companies compared; the peer median is $742.5K.
- Its year-over-year change of -70.7% is the 7th highest of 9, against a peer median of -8.0%.
- Other financing activities amounts to 5.0% of revenue for PROF, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $5.82M | +10455.5% | — | 44.7% | |
| LTM Mar 2026 | $3M | +26.4% | — | 2.8% | |
| LTM Mar 2026 | $2.62M | — | — | 2.3% | |
| LTM Mar 2026 | $1.76M | -42.3% | — | 3.9% | |
| LTM Mar 2026 | $1.17M | -82.3% | — | 0.8% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.17M | -47.0% | +5.4% | 63.0% |
| LTM Mar 2026 | $941K | -70.7% | — | 5.0% | |
| LTM Mar 2026 | $371K | +100.4% | — | 60.0% | |
| LTM Mar 2026 | $319K | +82.3% | — | 0.6% | |
| LTM Mar 2026 | $95K | -100.3% | -54.9% | 3.2% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding PROF) | $742.5K | -8.0% | -24.7% | 3.0% | |
Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.7M) | (28.67M) | (28.32M) | (27.82M) | (42.57M) |
| Depreciation & Amortization | 1.88M | 1.6M | 929K | 936K | 569.8K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.21M | 4.24M | 3.42M | 2.58M | 5.49M |
| Change in Working Capital | (877K) | (5.63M) | 540K | 591K | (1.74M) |
| Accounts Receivables | 2M | (1.42M) | (956K) | 186K | (175.01K) |
| Inventory | (2.49M) | (1.86M) | 353K | 656K | (2.87M) |
| Accounts Payables | (356K) | (566K) | 1.35M | 815K | 384.62K |
| Other Working Capital | (26K) | (1.78M) | (211K) | (1.07M) | 918.81K |
| Other Non-Cash Items | 132K | 2.66M | 828K | 255K | (622.65K) |
| Operating Cash Flow | (22.36M) | (25.8M) | (22.61M) | (23.45M) | (38.88M) |
| Capital Expenditures | (593K) | 0 | 0 | 0 | (179.08K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (561K) | 0 | 0 | 0 | 91.63K |
| Investing Cash Flow | (593K) | 0 | 0 | 0 | (246.24K) |
| Debt Repayment | (386K) | 6.92M | (912K) | (2.56M) | (1.33M) |
| Common Stock Issued | 0 | 0 | 0 | 62.11M | 43.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.33M | 114K | 2.67M | (4.85M) | 0 |
| Financing Cash Flow | 5.95M | 7.03M | 1.76M | 54.7M | 41.86M |
| Effect of Forex Changes | 244K | (1.87M) | 549K | (2.54M) | 2M |
| Net Change in Cash | (16.76M) | (20.64M) | (20.3M) | 28.7M | 4.73M |
| Free Cash Flow | (22.95M) | (25.8M) | (22.61M) | (23.45M) | (39.05M) |
Profound Medical Corp.
NASDAQ:PROF
Intrinsic Alpha fair value
Locked
Current Price
$6.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.